UZ Leuven
Leuven, 3000, Belgium
Location status: Recruiting
NCT Number: NCT02314949
An immunomodulatory protocol, experimentally-proven to promote T-regulatory dependent graft protective mechanisms was applied in a clinical cohort of 13 intestinal transplant recipients to activate - in a protolerogenic environment - T-regulatory cells.
This protocol is the standard of care in the investigators intestinal transplant programme since the first intestinal transplant was performed in october 2000.
Interested in participating?
Request InfoAll sexes
Observational
Leuven, 3000, Belgium
Location status: Recruiting
The LP is a 4-step approach that aims to upregulate T-regulatory cells (T-Regs) by directly stimulating their development and removing stimuli that could suppress them, eventually creating an environment favorable for graft acceptance. This protocol has been based upon preclinical research perormfed in the investigators lab and has been implemented as standard of care since the inception of the clinical programma in 2000. Patients gave informed consent for Donor Specific Blood Transfusion. Ethical approval for collection of additional blood samples was granted by the local ethical committee (s56862).
Step 1. Donor-specific blood transfusion (DSBT). 400 mL of whole blood was collected from the donor at the time of procurement and was transfused systemically in the recipient prior to reperfusion.
Step 2. Avoiding high-dose steroids. After Intestinal Transplantation, only 16 mg of medrol was administered and tapered towards 4 mg in 3 to 6 months post-Tx, similar to the liver Tx protocol.
Step 3. Avoiding high-dose calcineurin inhibitors (tacrolimus). Initial levels of 15 ng/ml were tapered -within 3 to 6 months- to 5 ng/mL or less for liver-containing grafts and 6 to 8 ng/mL for isolated intestinal grafts.
Step 4. Maintaining mucosal integrity and reducing ischemia reperfusion injury, inflammation, and endotoxin translocation. This was obtained by selecting perfect (ischemia-free) donors (<50y, absence of significant hypotension, vasopressor requirement and cardiac arrest); pretreating donors with selective bowel decontamination and glutamine; gentle manipulations of the organs during donor and recipient surgery; aiming for short cold and warm ischemic times (5h and 30' respectively). Bowel decontamination consists of Nilstat, Tobramycine and Colimycine administered by a nasogastric tube and continued posttransplant during three months. Glutamine is supplemented parenterally (Dipeptiven Kabi Fresenius) and enterally (Alitracq) to donors and continued posttransplant.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 10 years
routine clinical follow-up and Kaplan Meier Analysis
Time frame: 10 years
Peripheral blood mononuclear cells (PBMC's) isolation and flow cytometry
Time frame: 10 years
routine endoscopical obtained ileal biopsies analysed for number of apoptotic bodies in the crypt
Contact information is provided by the study sponsor or research team.
Jacques Pirenne, MD,PhD,MsC
CONTACT
Laurens J Ceulemans, MD
CONTACT
Universitaire Ziekenhuizen KU Leuven
Other
A Multifactorial Immunomodulatory Protocol -Promoting T-regulatory Cells- Prolongs Graft and Patient Survival After Intestinal Transplantation
Acronym: LP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03997253
Organ Transplantation
Limoges, France
View Trial DetailsNCT04687865
Organ Transplantation
Lyon, Rhône, France
View Trial DetailsNCT06652919
Organ Transplantation
Münster, North Rhine-Westphalia, Germany
View Trial DetailsNCT07288918
Mobile Applications, Nursing
Samsun, Turkey (Türkiye)
View Trial Details